Amfenac

Amfenac

SCHEMBL3500793

Nc1c(CC(=O)[O-])cccc1C(=O)c1ccccc1.O.O.[Na+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Amfenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amfenac SCHEMBL2254 1.00 — —
Amfenac SCHEMBL8347441 0.99 — —
Amfenac SCHEMBL29603368 0.98 — —
Amfenac SCHEMBL9644552 0.98 — —
Amfenac SCHEMBL11459150 0.97 ABCB11 (0.58) —
Amfenac SCHEMBL11467023 0.97 ABCB11 (0.58) —
Amfenac SCHEMBL11460876 0.97 ABCB11 (0.58) —
Amfenac SCHEMBL11726336 0.95 ABCB11 (0.59) —
Amfenac SCHEMBL9747739 0.95 ABCB11 (0.59) —
Amfenac SCHEMBL11730572 0.95 ABCB11 (0.59) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210379087-A1 COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2021-12-09 — — US claimed
CN-113347969-A Composition for eliminating senescent cells 维也纳自然资源与生命科学大学 2021-09-03 — — CN claimed
EP-3643305-A1 COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS Universität für Bodenkultur Wien (AT) 2020-04-29 — — EP claimed
US-4045576-A ANTI-INFLAMMATORY METHODS USING 2-AMINO-3-(5- AND 6-)BENZOYLPHENYLACETIC ACIDS, ESTERS AND METAL SALTS THEREOF AND THE COMPOUNDS A. H. ROBINS COMPANY, INCORPORATED (US) 1977-08-30 — — US claimed
US-20260137632-A1 NONAQUEOUS PREPARATION FOR PERCUTANEOUS ABSORPTION LEAD CHEMICAL CO., LTD. (JP) 2026-05-21 — — US disclosed
EP-4656206-A1 NON-AQUEOUS PERCUTANEOUSLY ABSORPTIVE FORMULATION Lead Chemical Co., Ltd. (JP) 2025-12-03 — — EP disclosed
US-12427192-B2 Water soluble adjuvant and composition containing same Sumitomo Pharma Co., Ltd. (JP) 2025-09-30 — — US disclosed
US-12383608-B2 WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides Sumitomo Pharma Co., Ltd. (JP) 2025-08-12 — — US disclosed
EP-3299028-B1 COMBINATION OF WT1 ANTIGEN PEPTIDE, IMMUNOMODULATOR AND WT1 HELPER PEPTIDE SUMITOMO PHARMA CO LTD (JP) 2024-10-30 — — EP disclosed
US-20240293521-A1 COMBINATION USE OF WT1 ANTIGEN PEPTIDE AND IMMUNOMODULATOR Sumitomo Pharma Co., Ltd. (JP) 2024-09-05 — — US disclosed
WO-2024157473-A1 NON-AQUEOUS PERCUTANEOUSLY ABSORPTIVE FORMULATION リードケミカル株式会社 2024-08-02 — — WO disclosed
US-20230364037-A1 CANCER THERAPEUTIC GILLIES MCINDOE RESEARCH INSTITUTE (NZ) 2023-11-16 — — US disclosed
US-20080226601-A1 Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods UNIVERSITY OF ROCHESTER (US) 2008-09-18 — — US disclosed
EP-1903873-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS THE UNIVERSITY OF ROCHESTER (US) 2008-04-02 — — EP disclosed
US-20080070303-A1 Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement ADVANCED CELL TECHNOLOGY 2008-03-20 — — US disclosed
WO-2007062198-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY ADVANCED CELL TECHNOLOGY, INC. (US) 2007-05-31 — — WO disclosed
WO-2006135602-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS UNIVERSITY OF ROCHESTER (US) 2006-12-21 — — WO disclosed
US-4182774-A Method of inhibiting blood platelet aggregation with 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof A. H. ROBINS COMPANY, INCORPORATED (US) 1980-01-08 — — US disclosed
US-4126635-A ANTICHOLESTEROL, BLOOD PLATELET AGGREGATION INHIBITION A. H. ROBINS COMPANY, INCORPORATED (US) 1978-11-21 — — US disclosed
US-4045576-A ANTI-INFLAMMATORY METHODS USING 2-AMINO-3-(5- AND 6-)BENZOYLPHENYLACETIC ACIDS, ESTERS AND METAL SALTS THEREOF AND THE COMPOUNDS A. H. ROBINS COMPANY, INCORPORATED (US) 1977-08-30 — — US disclosed
Send feedback